A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Phase 4 Completed 45 enrolled Takeda

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the efficacy and safety of long-term administration of the oral proteasome inhibitor ixazomib as part of ixazomib in combination with lenalidomide and dexamethasone (IRd) therapy in patients with relapsed and/or refractory multiple myeloma (RRMM) treated initially with an injectable proteasome inhibitor-based therapy.

Timeline

Start: 2018-02-18
Primary completion: 2021-05-28
Completion: 2021-05-28

Publications

Abe Y, Sasaki M, Takezako N, Ito S, Suzuki K, Handa H, Chou T, Yoshida T, Mori I, Shinozaki T, Suzuki K. Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma. Ann Hematol. 2023 Sep;102(9):2493-2504. doi: 10.1007/s00277-023-05212-7. Epub 2023 Jun 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ixazomib	Unknown	4 mg	Oral
Background	Bortezomib	Small molecule	—	—
Background	Carfilzomib	Other / unclassified	—	Intravenous
Background	Dexamethasone	Small molecule	40 mg	—
Background	Lenalidomide	Other / unclassified	25 mg	—

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Summary

Timeline

Publications

Drugs

Indications